---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-046481"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T13:37:23.026605+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KalVista appoints William Fairey to Board; commercial expertise in rare disease

## Summary
- William Fairey appointed to Board effective April 18, 2024 as Class III director.
- Mr. Fairey previously served as Chief Commercial Officer at MyoKardia and COO at ChemoCentryx.
- Initial compensation includes options to purchase 17,000 shares and $42,500 annual cash retainer.
- Appointment adds commercial launch experience ahead of planned FDA submission for sebetralstat.
- Mr. Fairey is independent under Nasdaq and SEC rules.

## SEC filing metadata
- accession: 0000950170-24-046481
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/0000950170-24-046481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/kalv-20240418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-046481
- JSON: https://secwatch.observer/filing/0000950170-24-046481.json
- Plain text: https://secwatch.observer/filing/0000950170-24-046481.txt

## Key facts
- Executive change
  William Fairey was appointed as Class III Director at KalVista Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/0000950170-24-046481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.